Supernus Pharmaceuticals | SUPN

Stock Price
33.53
Daily Change
1.73%
Yearly
18.56%
Q2 Forecast
32.65
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Eisai 9,500.00 450.00 4.97% 82.48%
Abbott 104.19 1.38 1.34% -10.62%
Aurora Cannabis 0.71 0.04 5.97% -64.68%
ANI Pharmaceuticals 48.00 1.58 3.40% 64.16%
Bristol-Myers Squibb 65.66 0.98 1.52% -12.65%
Cara Therapeutics 3.09 0 0% -64.97%
Corcept Therapeutics 23.26 0.29 1.26% 8.90%
Endo International 0.03 0 0% -94.89%
Horizon Pharma 99.93 -0.47 -0.47% 9.46%
Eli Lilly 442.22 5.84 1.34% 46.60%
Marinus Pharmaceuticals 7.39 0.17 2.35% 26.32%
Pacira 39.09 1.05 2.76% -39.22%
Pfizer 38.36 0.34 0.89% -27.89%
Perrigo 32.99 0.93 2.90% -16.18%
Revance Therapeutics 31.06 0.65 2.14% 133.53%
Supernus Pharmaceuticals 33.53 0.57 1.73% 18.56%
United Therapeutics 217.22 3.74 1.75% -4.99%
Canopy Growth Corp 1.14 0 0% -78.97%
Xeris Pharmaceuticals 2.82 0.20 7.63% 28.18%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%
US2000 1831 62.97 3.56% -2.77%

Supernus Pharmaceuticals

Supernus Pharmaceuticals traded at $33.53 this Friday June 2nd, increasing $0.57 or 1.73 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals gained 9.91 percent. Over the last 12 months, its price rose by 18.56 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 32.65 by the end of this quarter and at 29.91 in one year, according to Trading Economics global macro models projections and analysts expectations.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.